REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Oxygen Containing Hetero Ring > The Hetero Ring Is Six-membered > Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos > Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Tricyclo Ring System Having The Hetero Ring As One Of The CyclosTricyclo Ring System Having The Hetero Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010575 - Intracorporeal medicaments for photodynamic treatment of disease New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used ... 11/16/06 - 20060258738 - Use of dronabinol for treatment of side effects of hepatitis c therapy The present invention provides methods for treating and preventing the gastrointestinal side effects associated with anti-HCV therapy comprising administering delta-9-tetrahydrocannabinol. ... 11/02/06 - 20060247304 - Pharmaceutical compositions for the treatment of pain The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC. ... 10/05/06 - 20060223880 - Methods of protecting against radiation injury Administration of a modulator of cell cycle checkpoint activation, which is preferably β-lapachone, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, protects normal cells against radiation injury. The invention includes methods of preventing radiation damage. The invention also provides methods for treating conditions such as cancer with ... 09/28/06 - 20060217437 - Tgf-beta modulators and methods for using the same X4 is alkoxy, hydroxy, halide, amino, monoalkylamino, or dialkylamino. ... 09/07/06 - 20060199859 - Topical medicaments and methods for photodynamic treatment of disease New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment ... 09/07/06 - 20060199858 - Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate ... 08/17/06 - 20060183793 - Method of treating hematologic tumors and cancers Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 ... 07/27/06 - 20060167084 - Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis Methods are provided for, inter alia, treating and/or preventing symptoms associated with multiple sclerosis and MS relapse. ... 07/27/06 - 20060167083 - Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures Methods for the treatment of diseases associated with aberrant cell survival, aberrant cell proliferation, abnormal cell migration, abnormal angiogenesis, abnormal estrogen/androgen balance, dysfunctional or abnormal steroid genesis, degeneration including degenerative changes within blood vessel walls, inflammation, or immunological imbalances utilising isoflav-3-ene and isoflavan compounds of the general formula (II) are ... 07/20/06 - 20060160888 - Room-temperature stable dronabinol formulations A room temperature stable cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation is dronabinol in an oil-based carrier contained within a hard gelatin capsule. ... 07/13/06 - 20060154980 - Improved cox-2 inhibitory compositions and therapeutic regimen This invention provides improved COX-2 inhibitory compositions comprising a combination of a selective inhibitor of COX-2 and a prostacyclin promoter, especially an antioxidant of the type known as food extracts. The invention also provides a regimen treating a disease that is responsive to inhibition of cyclooxygenase-2, comprising administering to a ... 06/22/06 - 20060135599 - Use for pharmaceutical composition The invention relates to the use of one or more cannabinoids in the treatment of neuropathic or chronic pain. ... 06/15/06 - 20060128794 - Treatment of interstitial cystitis using (6ar,10ar)-delta8-tetrahydrocannabinol-11-oic acids The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention ... 06/08/06 - 20060122261 - [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications] The invention describes methods of preparation of isoforskolin extract, deacetylforskolin extract and related compounds from a natural source. Compositions and human and veterinary applications of such extracts in weight management through promoting lean body mass and in topical preparations for cellulite control, are also described. The compositions of the invention ... 05/04/06 - 20060094774 - Cannabinoid crystalline derivatives and process of cannabinoid purification Δ9 tetrahydrocannabinol (THC) esters comprising the reaction product of THC with at least one aryl sulfonyl chloride in the presence of at least one tertiary amine. The resulting aryl sulfonic THC esters are highly crystalline and stable at room temperature in air, allowing for indefinite storage. The aryl sulfonic THC ... 03/16/06 - 20060058373 - Novel substituted sulfamate anticonvulsant derivatives wherein X, R3, R4, R5 and R6 are as described in the specification. ... 02/16/06 - 20060035963 - Quinone prodrug compositions and methods of use The present invention relates to quinone prodrug compositions and therapeutic methods using such prodrug compositions. Preferably, the quinone compounds of the invention are napthoquinone compounds such as β-lapachone or β-lapachone analogs. The quinone prodrug compositions of the invention exhibit improved solubility, stability, bioavailability, and pharmacokinetic properties, as well as improved ... 12/22/05 - 20050282889 - Intracorporeal medicaments for photodynamic treatment of disease New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used ... 11/03/05 - 20050245599 - Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier ... 10/27/05 - 20050239874 - Novel analgesic and immunomodulatory cannabinoids X is a covalent bond, —CH2— or —CHR1—, wherein R1 a C1 to C3 substituted or unsubstituted alkyl group. Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring ... 10/06/05 - 20050222246 - Beta-lapachone is a broad spectrum anti-cancer agent The present invention provides for methods that utilize agents effective in the treatment of a wide range of cancerous and pre-cancerous conditions. Moreover, the present invention provides agents capable of acting as an inhibitor of cell proliferation in a broad range of cell types. ... 10/06/05 - 20050222245 - Pyranocoumarin derivatives The present invention relates to compounds of the following formula (I) or pharmaceutically acceptable salts thereof. The present invention also relates to use for a cognitive-enhancing agent of compounds of the following formula (I) or pharmaceutically acceptable salts thereof and to a process for preparing the same. Further, the present ... 09/01/05 - 20050192341 - Non-psychotropic cannabinoids for prevention of cognitive impairment The present invention relates to method of using pharmaceutical compositions that contain, as an active ingredient, non-psychotropic cannabinoids for preventing, alleviating or diminishing cognitive impairment resulting from certain types of surgery, diseases or viral infections, fetal distress, pre-term or low weight delivery, from medical intervention such as certain types of ... 07/28/05 - 20050165088 - Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use. ... 07/14/05 - 20050154049 - Intracorporeal medicaments for photodynamic treatment of disease New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used ... 06/30/05 - 20050143448 - Cb2 receptors blocks accumulation of human hepatic myofibroblasts: a novel antifibrogenic pathway in the liver Methods and compositions for treating diseases mediated by CB2 receptors are disclosed, including fibrosis associated with liver injury. ... 06/23/05 - 20050137251 - Dexanabinol and dexanabinol analogs regulate inflammation related genes The present invention relates to methods of treatment utilizing pharmaceutical compositions that include as active ingredients non-psychotropic cannabinoid derivatives that modulate the expression of genes involved in inflammatory and immune processes. Regulating the transcription of pro and anti-inflammatory mediators has useful therapeutic application for prevention and treatment of acute and ... ### FreshPatents.com Support |